Latest filings (excl ownership)
10-Q
2024 Q1
Quarterly report
2 May 24
8-K
Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update
2 May 24
8-K
Departure of Directors or Certain Officers
2 May 24
DEFA14A
Additional proxy soliciting materials
10 Apr 24
DEF 14A
Definitive proxy
10 Apr 24
8-K
Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna
4 Apr 24
10-K
2023 FY
Annual report
5 Mar 24
8-K
Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
29 Feb 24
8-K
Arbutus Announces 2024 Corporate Objectives and Provides Financial Update
8 Jan 24
8-K
Departure of Directors or Certain Officers
4 Jan 24
8-K
Preliminary data in subset of patients given imdusiran and then VTP-300 show early signs of immune activation
9 Nov 23
10-Q
2023 Q3
Quarterly report
7 Nov 23
8-K
Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update
7 Nov 23
8-K
Departure of Directors or Certain Officers
7 Nov 23
8-K
Arbutus Announces Multiple Abstracts Accepted for Presentation at AASLD - The Liver MeetingĀ® 2023
11 Oct 23
8-K
Arbutus Announces Pipeline Updates and Dosing of the First Subject in the Phase 1a/1b Clinical Trial with AB-101; Cash Runway Extended
11 Sep 23
S-8
Registration of securities for employees
3 Aug 23
10-Q
2023 Q2
Quarterly report
3 Aug 23
8-K
Arbutus Reports Second Quarter 2023 Financial Results and Corporate Update
3 Aug 23
8-K
Arbutus Appoints Melissa V. Rewolinski, PhD to its Board of Directors
12 Jul 23
8-K
Arbutus Appoints Two New Executives
10 Jul 23
8-K
Other Events
21 Jun 23
8-K
Arbutus Presents Preliminary AB-729 and Pegylated Interferon Alfa-2a Combination Data at the EASL Congress 2023
21 Jun 23
8-K
Arbutus to Present AB-729 and AB-836 Data at EASL Congress 2023
7 Jun 23
8-K
Submission of Matters to a Vote of Security Holders
30 May 23
10-Q
2023 Q1
Quarterly report
4 May 23
8-K
Arbutus Reports First Quarter 2023 Financial Results and Corporate Update
4 May 23
8-K
Arbutus Provides AB-729 Clinical Data and AB-161 Preclinical Data as Oral Presentations at the Global Hepatitis Summit 2023
27 Apr 23
8-K
Arbutus Announces FDA Clinical Hold on IND Application for AB-101, an oral PD-L1 inhibitor
25 Apr 23
8-K
Arbutus to Present AB-729 and AB-161 Data at the Global Hepatitis Summit 2023
18 Apr 23
DEFA14A
Additional proxy soliciting materials
12 Apr 23
DEF 14A
Definitive proxy
12 Apr 23
8-K
Arbutus Biopharma and Genevant Sciences File Patent Infringement Lawsuit Against Pfizer/BioNTech
4 Apr 23
8-K
Arbutus Doses First Subject in Phase 1 Clinical Trial with its Oral RNA Destabilizer, AB-161
16 Mar 23
8-K
Arbutus Presents AB-343 Data at the 36th International Conference on Antiviral Research
14 Mar 23
10-K
2022 FY
Annual report
2 Mar 23
8-K
Arbutus Reports Fourth Quarter and Year End 2022 Financial Results and Corporate Update
2 Mar 23
8-K
Arbutus Announces Resignation of Board Member
27 Jan 23
8-K
Arbutus Announces 2023 Corporate Objectives and Provides Financial Update
5 Jan 23
8-K
Initial data from IFN phase expected in the first half of 2023
13 Dec 22
Latest ownership filings
SC 13G/A
Whitefort Capital Management, LP
14 Feb 24
SC 13G/A
Two Seas Capital LP
14 Feb 24
SC 13G/A
BlackRock Inc.
12 Feb 24
4
J. Christopher Naftzger
5 Feb 24
4
Karen Sims
5 Feb 24
4
DAVID C HASTINGS
5 Feb 24
4
Michael J. Sofia
5 Feb 24
4
Michael J. McElhaugh
5 Feb 24
SC 13G
Two Seas Capital LP
21 Nov 23
SC 13G
Whitefort Capital Management, LP
11 Sep 23
4
Melissa Rewolinski
13 Jul 23
3
Melissa Rewolinski
13 Jul 23
3
J. Christopher Naftzger
12 Jul 23
3
Karen Sims
12 Jul 23
4
J. Christopher Naftzger
12 Jul 23
4
Karen Sims
12 Jul 23
4
RICHARD C HENRIQUES JR
26 May 23
4
DANIEL D BURGESS
26 May 23
4
KEITH S MANCHESTER
26 May 23
4
Frank Torti
26 May 23
4
James R Meyers
26 May 23
4
Michael J. McElhaugh
3 Feb 23
4
Michael J. Sofia
3 Feb 23
4
DAVID C HASTINGS
3 Feb 23
4
William H. Collier
3 Feb 23
4
Elizabeth Howard
3 Feb 23
SC 13G
BlackRock Inc.
3 Feb 23
4
RICHARD C HENRIQUES JR
26 May 22
4
DANIEL D BURGESS
26 May 22
4
James R Meyers
26 May 22
4
Frank Torti
26 May 22
4
KEITH S MANCHESTER
26 May 22
4
Tram Tran
26 May 22
SC 13G/A
RTW INVESTMENTS, LP
14 Feb 22
4
William H. Collier
20 Jan 22
4
DAVID C HASTINGS
20 Jan 22
4
Elizabeth Howard
20 Jan 22
4
Michael J. Sofia
20 Jan 22
4
Gaston Picchio
20 Jan 22
4
Michael J. McElhaugh
20 Jan 22